Format

Send to

Choose Destination
Blood Adv. 2018 Dec 11;2(23):3492-3505. doi: 10.1182/bloodadvances.2018025106.

p53 regulates CD46 expression and measles virus infection in myeloma cells.

Author information

1
CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
2
Service d'Hématologie Clinique, Unité d'Investigation Clinique, and.
3
Laboratoire d'Hématologie, CHU de Nantes, Nantes, France.
4
National Reference Laboratory for Measles Virus, Département de Virologie, CHU de Caen, Université de Normandie, Caen, France; and.
5
CNRS UMR3569, Unité de Génomique Virale et Vaccination, Institut Pasteur, Paris, France.

Abstract

In this study, we assessed the sensitivity of myeloma cells to the oncolytic measles virus (MV) in relation to p53 using 37 cell lines and 23 primary samples. We showed that infection and cell death were correlated with CD46 expression, which was associated with TP53 status; TP53 abn cell lines highly expressed CD46 and were preferentially infected by MV when compared with the TP53 wt cell lines (P = .046 and P = .045, respectively). Infection of myeloma cells was fully dependent on CD46 expression in both cell lines and primary cells. In the TP53 wt cell lines, but not the TP53 abn cell lines, activation of the p53 pathway with nutlin3a inhibited both CD46 expression and MV infection, while TP53 silencing reciprocally increased CD46 expression and MV infection. We showed using a p53 chromatin immunoprecipitation assay and microRNA assessment that CD46 gene expression was directly and indirectly regulated by p53. Primary myeloma cells overexpressed CD46 as compared with normal cells and were highly infected and killed by MV. CD46 expression and MV infection were inhibited by nutlin3a in primary p53-competent myeloma cells, but not in p53-deficient myeloma cells, and the latter were highly sensitive to MV infection. In summary, myeloma cells were highly sensitive to MV and infection inhibition by the p53 pathway was abrogated in p53-deficient myeloma cells. These results argue for an MV-based clinical trial for patients with p53 deficiency.

PMID:
30530776
PMCID:
PMC6290095
DOI:
10.1182/bloodadvances.2018025106
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center